S100B in cardiac surgery brain monitoring: friend or foe?

Giuseppe Lapergola,Alessandro Graziosi,Ebe D'Adamo, Patrizia Brindisino, Mariangela Ferrari, Anna Romanelli,Mariachiara Strozzi, Roberta Libener,Danilo A W Gavilanes,Antonio Maconi,Angela Satriano, Alessandro Varrica,Diego Gazzolo

CLINICAL CHEMISTRY AND LABORATORY MEDICINE(2022)

引用 2|浏览7
暂无评分
摘要
Recent advances in perioperative management of adult and pediatric patients requiring open heart surgery (OHS) and cardiopulmonary bypass (CPB) for cardiac and/or congenital heart diseases repair allowed a significant reduction in the mortality rate. Conversely morbidity rate pattern has a flat trend. Perioperative period is crucial since OHS and CPB are widely accepted as a deliberate hypoxic-ischemic reperfusion damage representing the cost to pay at a time when standard of care monitoring procedures can be silent or unavailable. In this respect, the measurement of neuro-biomarkers (NB), able to detect at early stage perioperative brain damage could be especially useful. In the last decade, among a series of NB, S100B protein has been investigated. After the first promising results, supporting the usefulness of the protein as predictor of short/long term adverse neurological outcome, the protein has been progressively abandoned due to a series of limitations. In the present review we offer an up-dated overview of the main S100B pros and cons in the peri-operative monitoring of adult and pediatric patients.
更多
查看译文
关键词
brain injury, cardiac surgery, cardiopulmonary bypass, neurobiomarker, neuromonitoring, S100B
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要